144 ·Filed Jun 29, 2026

VIR

Vir Biotechnology, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago SEC0001959173-26-004947
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a small, routine sale by a former director following an option exercise. No material impact expected. Monitor for any larger insider sales ahead of upcoming catalysts.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d
VIR ▼ -16.28% at T+20d
NEUTRAL call ✗ call lost -16.28% · α vs SPY -16.00% · entry $10.38 → $8.69
Next anchor: T+60d due 9d ago
Latest observation: T+58 +37.60% FF3 residual α
Entry anchored
Jun 29, 03:05 PM ET
via exchange tick
T+1d
-1.83%
call -1.83% · α -2.61%
$10.19
settled 3mo ago
T+5d
-3.47%
call -3.47% · α -4.86%
$10.02
settled 3mo ago
T+20d
-16.28%
call -16.28% · α -16.00%
$8.69
settled 2mo ago
T+60d
—
call — · α —
—
due 9d ago

Price Chart

Loading chart...

Executive Summary

Former director Saira Ramasastry filed a Form 144 on June 29, 2026, indicating intent to sell 16,000 shares of Vir Biotechnology (VIR) with an approximate market value of $165,139. The sale follows a stock option exercise and represents a routine diversification move by a former board member, not a current executive. Given the small size relative to VIR's $1.7B market cap and the insider's former-director status, the signal is minimal.

Key Facts

  • Insider: Saira Ramasastry, former director
  • Shares to be sold: 16,000 shares of common stock
  • Estimated value: ~$165,139
  • Source of shares: stock option exercise (issuer grant)
  • Broker: Fidelity Brokerage Services LLC
  • Filing date: June 29, 2026

Financial Impact

Sale of 16,000 shares valued at ~$165K, representing less than 0.01% of VIR's $1.7B market cap

dilution

Risk Factors

  • Insider selling could increase if more directors or executives file similar notices
  • Option exercise may signal limited upside conviction from this insider

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-004947
Document: 0001959173-26-004947-index.html0001959173-26-004947
Document: 0001959173-26-004947.txt0001959173-26-004947
18 reports for VIR
Performance horizon
40% Hit rate 2 of 5 directional calls best @ T+60▲ +10.12%Feb 24, 2026
Filters
Rows
Reports for VIR — sortable, filterable
TypeNow
Aug 14, 2026
7w ago
Court Ruling
NEUTRAL ★ 1/10
$9.24 $9.78▲ +5.84%▲ +7.21%$11.17 (+20.89%)
Aug 9, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$8.89 $9.39▲ +5.62%▲ +5.67%$11.17 (+25.65%)
Jul 24, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$8.69 $8.90▲ +2.42%▲ +2.04%$11.17 (+28.54%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 2/10
$10.38 $10.02▼ −3.47%▼ −4.86%$11.17 (+7.61%)
Jun 10, 2026
16w ago
3
NEUTRAL ★ 1/10
$8.52 $9.30▲ +9.15%▲ +8.72%$11.17 (+31.10%)
Jun 10, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$8.52 $9.30▲ +9.15%▲ +8.72%$11.17 (+31.10%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.77 $8.25▼ −5.93%▼ −2.11%$11.17 (+27.37%)
May 28, 2026
18w ago
8-K
NEUTRAL ★ 2/10
$9.55 $8.77▼ −8.17%▼ −8.12%$11.17 (+16.96%)
Apr 16, 2026
24w ago
DEFA14A
NEUTRAL ★ 3/10
$10.33 $10.35▲ +0.19%▼ −0.79%$11.17 (+8.13%)
Apr 10, 2026
25w ago
8-K
NEUTRAL ★ 3/10
$9.31 $11.09▲ +19.12%▲ +15.82%$11.17 (+19.98%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (65h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access